Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study

<b>Aim:</b> First-line (1L) immunotherapy has yielded superior overall survival (OS) in metastatic melanoma (MM) but some patients are ineligible for immunotherapy or need rapid response with 1L targeted therapy (TT).<b>Materials & methods:</b> Retrospective cohort study of real-world patients treated with 1L immunotherapy (144 <i>BRAF</i> wild type, 85 <i>BRAF</i>-mutated) or 1L TT (143 <i>BRAF</i>-mutated) for MM in Finland during 2014-2021.<b>Results:</b> Baseline brain metastases, liver metastases and elevated LDH were less common, 2-year OS rates were higher (60.3-63.5% vs. 33.8%) and more patients were alive without the next-line treatment (38.0-43.8% vs. 23.3%) in patients with 1L immunotherapy.<b>Conclusion:</b> Real-world patients with 1L immunotherapy for MM had favorable baseline characteristics and better treatment outcomes than observed in patients with 1L TT.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2024-09-30
DOI
https://doi.org/10.1080/14796694.2024.2403329
Citations
1
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.28
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study

Siru Mäkelä, Kalle Mattila, Sari Hernesniemi, Anna Kreutzman et al.
1 citations
Future Oncology
CAR-T cell therapy research
0.28
article

Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study

Siru Mäkelä, Kalle Mattila, Sari Hernesniemi, Anna Kreutzman, Olivia Hölsä, Päivikki Hemmilä, Johanna Vikkula, Leena Tiainen, Kai Kysenius, Mia Engström-Risku, Anssi Pystynen
article en
1 citations

Abstract

<b>Aim:</b> First-line (1L) immunotherapy has yielded superior overall survival (OS) in metastatic melanoma (MM) but some patients are ineligible for immunotherapy or need rapid response with 1L targeted therapy (TT).<b>Materials & methods:</b> Retrospective cohort study of real-world patients treated with 1L immunotherapy (144 <i>BRAF</i> wild type, 85 <i>BRAF</i>-mutated) or 1L TT (143 <i>BRAF</i>-mutated) for MM in Finland during 2014-2021.<b>Results:</b> Baseline brain metastases, liver metastases and elevated LDH were less common, 2-year OS rates were higher (60.3-63.5% vs. 33.8%) and more patients were alive without the next-line treatment (38.0-43.8% vs. 23.3%) in patients with 1L immunotherapy.<b>Conclusion:</b> Real-world patients with 1L immunotherapy for MM had favorable baseline characteristics and better treatment outcomes than observed in patients with 1L TT.

Future OncologyVol. 20(40)
University of Helsinki (FI), University of Turku (FI), Tampere University (FI), Helsinki University Hospital (FI), NHS Tayside (GB), Turku University Hospital (FI), National Cancer Centre Japan (JP), Tampere University Hospital (FI), Tampere University (FI), Comprehensive Blood & Cancer Center (US), Centre for Inflammation Research (GB), U-M Rogel Cancer Center (US)
Openalex Percentile: Top 35%
CAR-T cell therapy research
0.28
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.